Correlation Between Durect and Supernus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Durect and Supernus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Durect and Supernus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Durect and Supernus Pharmaceuticals, you can compare the effects of market volatilities on Durect and Supernus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Durect with a short position of Supernus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Durect and Supernus Pharmaceuticals.

Diversification Opportunities for Durect and Supernus Pharmaceuticals

0.07

Correlation Coefficient

Durect  Supernus Pharmaceuticals

Significant diversification

The 3 months correlation between Durect and Supernus is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding Durect and Supernus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Supernus Pharmaceuticals and Durect is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Durect are associated (or correlated) with Supernus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Supernus Pharmaceuticals has no effect on the direction of Durect i.e., Durect and Supernus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Durect and Supernus Pharmaceuticals

Given the investment horizon of 90 days Durect is expected to generate 1.39 times more return on investment than Supernus Pharmaceuticals. However, Durect is 1.39 times more volatile than Supernus Pharmaceuticals. It trades about 0.0 of its potential returns per unit of risk. Supernus Pharmaceuticals is currently generating about -0.07 per unit of risk. If you would invest  85.00  in Durect on December 29, 2024 and sell it today you would lose (4.00) from holding Durect or give up 4.71% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Durect  vs.  Supernus Pharmaceuticals

Durect

Risk-Adjusted Performance

Very Weak

Over the last 90 days Durect has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Durect is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Supernus Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Supernus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest inconsistent performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with Durect and Supernus Pharmaceuticals

The main advantage of trading using opposite Durect and Supernus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Durect position performs unexpectedly, Supernus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will offset losses from the drop in Supernus Pharmaceuticals' long position.

The idea behind Durect and Supernus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.